Ultragenyx Reports Results From 1st Cohort Of Phase 1/2 Study Of DTX401 Gene Therapy In Glycogen Storage Disease Type Ia;  Response Observed In All Three Patients And Two Patients Demonstrated Clinically Meaningful Improvement In Time To Hypoglycemia